OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway
OnKure Therapeutics (OKUR) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) of -$0.36. Despite the quarterly loss, the company maintains a robust liquidity position with $163.3 million in cash, cash equivalents, and marketable securities as of September 30, 2024. The company's current strategic focus is on advancing its next-generation PI3Kα pan-mutant-selective candidates. Specifically, OnKure is executing IND-enabling activities for OKI-345, targeting breast cancer, and OKI-355, targeting vascular anomalies, with plans to submit Investigational New Drug (IND) applications in the first half of 2027.
Topics: biotechnology cash runway clinical development earnings report
Read the full article at Seeking Alpha
Part of the story OnKure Therapeutics Reports Q3 GAAP EPS of -$0.36 and Strong Cash Runway (7 articles)